Menopause does not accelerate weight gain. In the largest cohort that followed women through it with DXA scans, weight "climbed linearly during premenopause without acceleration" at the transition — the scale kept doing what it had already been doing (Greendale 2019). What changed was what the weight was made of: fat gain roughly doubled, lean mass flipped from slowly increasing to slowly decreasing, and fat moved toward the abdomen. That distinction is the whole subject of this article, and it also explains where GLP-1 medication has something to offer and where nobody has yet done the study.
The menopause transition: the years around the final menstrual period, running roughly from the onset of cycle irregularity to two years after the last period. Body-composition changes in the research below are anchored to that window, not to a birthday.
Does menopause make you gain weight?
The best available evidence says no. The Study of Women's Health Across the Nation followed 1,246 women — 356 Black, 153 Chinese, 178 Japanese, 559 White — with repeated DXA scans, and modelled the trajectories around the final menstrual period. Its conclusion is stated flatly: "there is no discernable change in rate of weight gain at the start of the MT" (Greendale 2019). Weight rose steadily through the premenopausal years and its trajectory became flat after the transition.
The literature is not unanimous. A smaller four-year cohort of 156 women, with no Asian participants, found that weight and body fat rose significantly only in the women who actually became postmenopausal (Lovejoy 2008). SWAN is the larger, longer and better-controlled study, and it is the one that measured what was happening to the scale separately from what was happening to the tissue underneath it.
The practical consequence is that a woman who has gained weight through her forties has probably been gaining it for years, on a trend that predates any hormonal change. Attributing it to menopause misplaces both the cause and the timeline.
What actually changes
Composition and distribution. In SWAN, absolute fat mass was rising 1.0% per year before the transition and 1.7% per year during it; the proportion of the body that was fat rose from 0.4% to 1.0% per year. Lean mass went the other way — increasing 0.2% per year beforehand, decreasing 0.2% per year during the transition (Greendale 2019). Both trajectories flattened about two years after the final period. In absolute terms the lean-mass change is small, around 0.06 kg per year; what matters is that the direction reverses.
Where the fat sits changed more sharply. In the SWAN regional-fat analysis of 380 women, android fat — the fat around the middle — accelerated from 1.21% per year before the transition to 5.54% per year during it, and visceral fat began rising at 6.24% per year — rates that are the paper's White-referent trajectories, with statistically significant differences reported for some Black and Japanese trajectories, which for a Singapore reader is not a footnote (Greendale 2021).
That paper carries a warning worth heeding if you track progress with a tape measure. Waist girth grew at 0.55%, 0.96% and 0.55% per year across the three phases — rates that were not statistically different from each other — while the fat underneath was redistributing substantially. The authors' own conclusion is that "waist or hip circumferences are less sensitive to changes in fat distribution". A stable waist measurement through these years is not evidence that nothing is happening.
Does your metabolism slow at menopause?
Measured directly, resting energy expenditure did not fall. A five-year cohort of 102 women — mean BMI 23.3, a lean group rather than a clinic population — measured resting energy expenditure by indirect calorimetry and physical-activity energy expenditure by accelerometer, and found that total energy expenditure fell — but that the fall was "mostly due to a decrease in physical activity EE", while "average resting EE remained stable over time in postmenopausal women" (Duval 2013). Time spent in moderate activity fell and sedentary time rose.
So the familiar sentence — your metabolism slows at menopause — is not supported by the study that measured it most directly. What the same study found instead is more useful, because movement is something a person can act on.
Two caveats keep this honest. The Lovejoy cohort's 34-woman calorimetry subset did find a steeper fall in sleeping energy expenditure in women who became postmenopausal, −7.9% against −5.3%, plus a 32% fall in fat oxidation (Lovejoy 2008); those two findings disagree and both are on the record. And separately, the largest doubly-labelled-water dataset ever assembled found energy expenditure adjusted for fat-free mass to be stable across the entire 20-to-60 age span, with decline beginning only after about 60 (Pontzer 2021). That study never analysed menopausal status, so it does not rule a menopause effect in or out — but a study designed to find life-stage inflections in metabolic rate found none in the window where menopause happens. A related point sits in lean mass and metabolism: losing lean tissue does lower energy expenditure, which is a reason to defend it.
What is known about GLP-1 medication after menopause
Less than most people assume. No dedicated randomised trial of semaglutide or tirzepatide has been conducted in postmenopausal women. That is a finding from searching, not an omission here.
The closest available evidence is a retrospective post hoc analysis in which women already enrolled in the SURMOUNT trials were categorised afterwards into pre-, peri- and postmenopausal stages. In SURMOUNT-1, weight reduction with tirzepatide was 26%, 23% and 23% across those three groups, against 2%, 3% and 3% on placebo (Tchang 2025). Being postmenopausal, in other words, did not appear to blunt the response.
The caveats are substantial and belong in the same breath. It is a post hoc categorisation of trials never designed or powered for the question, no subgroup sample sizes or interaction p-values are reported, and several authors are employed by the manufacturer. It reports no body-composition outcome at all. Tirzepatide also has no Singapore weight-management indication, so this is trial education rather than a description of anything on offer.
And that leads to the half of the title that says "where it doesn't". Nobody has measured what happens to muscle in postmenopausal women on these medicines — which is precisely the group with the least lean mass to spare, since lean mass has already begun falling. The nearest thing is a small four-month study using semaglutide 1 mg, a diabetes-range dose rather than a weight-management one, in which fat-mass loss and lean-mass change did not differ significantly between postmenopausal and premenopausal women (Nicolau 2025). Both groups lost lean mass, the standard deviations were larger than the group differences, and the sample size is not stated. It is the only body-composition comparison by menopausal status that exists, and it cannot carry a conclusion.
Menopausal hormone therapy: what the evidence shows
This is reported here, not recommended. We do not prescribe menopausal hormone therapy, start it, stop it, or advise on it — it belongs with your own doctor or gynaecologist.
On muscle, the evidence is a clean null. Pooling 12 randomised trials in 4,474 postmenopausal women, hormone therapy users lost 0.06 kg less lean body mass than controls, which was not significant, and the authors concluded that "interventions other than HT should be explored" for muscle retention (Javed 2019). An observational cohort of 1,053 women reached the same place from a different direction: current users had lower visceral adipose tissue than never-users and did not show the ten-year gain in visceral and android fat that never-users showed — with no difference in lean body mass or grip strength (Papadakis 2018). Older randomised evidence pooling 107 trials associated hormone replacement therapy with about a 6.8% reduction in abdominal fat in women without diabetes (Salpeter 2006), on 2006-era preparations.
The claim circulating in press coverage — that hormone therapy boosts GLP-1 weight loss — deserves its sample size attached. It traces to a retrospective cohort of 106 postmenopausal women in which the hormone-therapy arm was 16 people, against 90 not on it, with baseline differences between the groups in race, dyslipidaemia and depression, and no body-composition outcome measured (Hurtado 2024). Sixteen patients in a non-randomised comparison is a signal worth someone studying properly. It is not a reason to start a hormone.
What has actually been shown to protect muscle
Resistance training, and the evidence for it in this population is direct. Pooling 26 studies in 745 postmenopausal and older women aged 50 to 80, resistance training produced a small-to-moderate significant increase in lean body mass, and the increases held regardless of age, intervention length, weekly frequency or number of exercises (Thomas 2021). That pooled analysis is of observational studies, so the stronger randomised evidence sits in the general literature: across 114 trials and 4,184 people, lean mass was statistically unchanged when resistance training accompanied caloric restriction (Lopez 2022).
Put beside the SWAN trajectories, the case is straightforward. Lean mass starts falling around the transition at roughly 0.2% per year, and the intervention with demonstrated effect on lean mass in exactly this population is resistance training two or three times a week. Nothing about the hormonal picture changes that, and no medicine has been shown to substitute for it. The companion article on getting lean after 40 covers the protein side of the same problem.
What this means for a Singapore reader
Two details from the research are specific enough to matter here.
SWAN's ethnicity results do not run uniformly. Japanese participants' fat mass did not increase significantly during the transition, and Chinese participants' fat mass declined afterwards, while lean-mass trajectories were similar across all four groups studied (Greendale 2019). The fat-gain half of the story is less certain for Asian women than the headline suggests; the lean-mass half looks the same for everyone.
Separately, an MRI study matched 22 non-obese postmenopausal Chinese-Singaporean women to 22 Caucasian women of the same age and BMI. Total abdominal fat was similar between the groups — but the Singaporean women carried a higher proportion of it viscerally, and in that group BMI did not correlate with visceral adiposity at all (Kalimeri 2021). With 22 women per group this is a small study, and it is women only. What it suggests is that for a postmenopausal Singaporean woman, BMI is a particularly weak proxy for what is happening to abdominal fat — and the SWAN regional-fat paper has already shown that a tape measure is not much better.
Common questions
Does menopause make you gain weight?
Not according to the largest study that measured it. In 1,246 women followed with DXA, weight "climbed linearly during premenopause without acceleration at the MT", and the authors state there is "no discernable change in rate of weight gain at the start of the MT" (Greendale 2019). What changed was composition: fat gain accelerated and lean mass reversed from gaining to losing.
Does your metabolism slow down at menopause?
Resting energy expenditure was measured directly in a five-year cohort and stayed stable; what fell was total energy expenditure, driven mainly by less physical activity and more sedentary time (Duval 2013). One smaller cohort found a steeper fall in sleeping energy expenditure in women who became postmenopausal, in a 34-woman subset (Lovejoy 2008) — the two disagree.
Has GLP-1 medication been tested in postmenopausal women?
Not in a dedicated trial. No randomised trial of semaglutide or tirzepatide has been conducted specifically in postmenopausal women. The closest evidence is a retrospective post hoc categorisation of women already enrolled in the SURMOUNT trials, which found weight loss of 26%, 23% and 23% in pre-, peri- and postmenopausal women on tirzepatide (Tchang 2025).
Does anyone know what GLP-1 medication does to muscle after menopause?
No. No study has measured lean mass in postmenopausal women on semaglutide or tirzepatide against a comparator designed to answer the question. The nearest is a small four-month study at semaglutide 1 mg, in which fat-mass loss and lean-mass change did not differ significantly between postmenopausal and premenopausal women — with standard deviations larger than the differences (Nicolau 2025).
Should I take hormone therapy to help with weight or muscle?
That is a conversation with your own doctor or gynaecologist, not with a weight-management service — we neither prescribe it nor advise on it. What the evidence shows is that pooling 12 randomised trials in 4,474 women, hormone therapy had no significant effect on lean body mass, and the authors concluded interventions other than hormone therapy should be explored for muscle (Javed 2019).